Publicaciones en las que colabora con Antonio Fontanellas Roma (16)

2024

  1. Exploring current and emerging therapies for porphyrias

    Liver International, Vol. 44, Núm. 9, pp. 2174-2190

  2. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  3. Porphyrins and the porphyrias

    Liver International

  4. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. Hydroxymethylbilane synthase (aka porphobilinogen deaminase): A novel metabolic tumor suppressor gene in hepatocellular carcinoma

    Journal of hepatology

  2. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96

  3. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

2021

  1. Acute intermittent porphyria, givosiran, and homocysteine

    Journal of Inherited Metabolic Disease

  2. Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection

    Biomedicine and Pharmacotherapy, Vol. 137

  3. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2019

  1. Current and innovative emerging therapies for porphyrias with hepatic involvement

    Journal of Hepatology, Vol. 71, Núm. 2, pp. 422-433

  2. Messenger RNA therapy for rare genetic metabolic diseases

    Gut, Vol. 68, Núm. 7, pp. 1323-1330

2018

  1. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2016

  1. Emerging therapies for acute intermittent porphyria

    Expert Reviews in Molecular Medicine, Vol. 18

2009

  1. Epidermal growth factor receptor ligands in murine models for erythropoietic protoporphyria: Potential novel players in the progression of liver injury

    Cellular and Molecular Biology, Vol. 55, Núm. 1, pp. 29-37